+ 12,3 % bei Geron (902213) Was ist los? o. T.


Seite 16 von 16
Neuester Beitrag: 12.05.23 09:50
Eröffnet am:04.06.04 17:51von: BiomediAnzahl Beiträge:394
Neuester Beitrag:12.05.23 09:50von: BiomediLeser gesamt:100.037
Forum:Börse Leser heute:6
Bewertet mit:
4


 
Seite: < 1 | ... | 10 | 11 | 12 | 13 | 14 | 15 |
>  

10835 Postings, 2180 Tage VassagoGERN 1.02$

 
  
    #376
05.03.22 10:59

Zahlen für Q3/21

  • kein Umsatz
  • Verlust 27 Mio. $
  • Cash 176 Mio. $
  • MK 328 Mio. $

https://d18rn0p25nwr6d.cloudfront.net/...4835-9fc7-6576fce03f8c.html#

 

2298 Postings, 1539 Tage BananiNa super

 
  
    #377
29.03.22 22:33
Geron Corporation Announces Proposed Public Offering of Common Stock and Warrants

https://finance.yahoo.com/news/...nces-proposed-public-200100969.html

Und wir sind schon bei 323.73M outstanding shares.  

Optionen

2298 Postings, 1539 Tage BananiDetails

 
  
    #378
30.03.22 08:53
…today announced the pricing of its previously announced underwritten public offering of 53,333,334 shares of its common stock and pre-funded warrants to purchase 18,095,238 shares of its common stock, together with accompanying warrants to purchase 35,714,286 shares of its common stock. The combined offering price to the public of each share of common stock and accompanying warrant is $1.05. The combined offering price to the public of each pre-funded warrant and accompanying warrant is $1.049. The common stock and pre-funded warrants will be sold in combination with an accompanying warrant to purchase 0.5 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying warrant has an exercise price of $1.45 per share and expires five years from the date of issuance; however, such term will be shortened upon achievement of a regulatory milestone.

All of the securities in the offering are being sold by Geron. The gross proceeds to Geron from this underwritten public offering are expected to be approximately $75.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Geron. The offering is expected to close on or about April 1, 2022, subject to the satisfaction of customary closing conditions.

Geron currently intends to use the net proceeds from this public offering, together with its existing cash, cash equivalents, restricted cash and marketable securities to fund potential regulatory filings in the United States and European Union for imetelstat in lower risk myelodysplastic syndromes (MDS), assuming top-line results in the IMerge Phase 3 clinical trial are supportive, and to support toward the completion of the IMpactMF clinical trial in refractory myelofibrosis and the planned exploratory studies in new indications, including IMproveMF and investigator-led trials in acute myeloid leukemia and higher risk MDS, the preclinical work in lymphoid malignancies and the discovery research program related to next generation telomerase inhibitors.

https://www.stonkmoon.com/news/GERN/1242cffb229cc72c9f1cc5f4ee5461f2
 

Optionen

287 Postings, 2276 Tage AndrolytGeron

 
  
    #379
30.03.22 16:47
Gestern nach Börsenschluss mit -25% und heute deutlich im Plus....Was für eine Kurs-Verwerfung ,sieht man auch nicht jeden Tag  

2298 Postings, 1539 Tage BananiDen Kursverlauf

 
  
    #380
30.03.22 19:56
muss mal jemand verstehen, aber gut, mir soll es recht sein.  

Optionen

10835 Postings, 2180 Tage VassagoGERN 1.60$ (+25%)

 
  
    #381
31.03.22 09:05

75 Mio. $ Offering

  • 53,3 Mio. Aktien + warrants zu 1,05$

https://ir.geron.com/investors/press-releases/...arrants/default.aspx

Rational nachvollziehbar ist dieser Kursananstieg (nach Bekanntgabe dieses Offerings) jedenfalls nicht.

 

5267 Postings, 8333 Tage BiomediSie lebt ja noch.

 
  
    #382
04.08.22 17:02
 

Optionen

17 Postings, 1851 Tage ZetlitzGute Testergebnisse

 
  
    #383
04.08.22 18:57
GERN's drug imetelstat called the Future Oncology. "Published by John Mascarenhas, MD and team on May 2, 2022.
Dr. Mascarenhas received research grant/funding from Incyte, Novartis, CTI BioPharma, Geron, PharmaEssentia, AbbVie, Bristol Myers Squibb, Celgene, Roche, Kartos, Promedior, and Merck in addition to many others. (Pay attention to big pharmas who are sponsoring the study)
The study designed to compare Imetelstat against two BAT; JAK inhibitors, ruxolitinib and fedratinib. An excellent study with no risk to patients.
Imetelstat vs. BAT, follow up visit after treatment ended. If progressive disease with BAT, patients were eligible for crossover to Imetelstat."
“They concluded that the study has the potential to change the treatment landscape in refractory MF and address a critical unmet need for disease-modifying therapies that will improve survival in this poor-prognosis patient population.”
(BAT is best available current treatments)  

Optionen

5267 Postings, 8333 Tage BiomediDanke für die Info.

 
  
    #384
04.08.22 22:38
 

Optionen

10835 Postings, 2180 Tage VassagoGERN 2.22$ (-8%)

 
  
    #385
01.11.22 08:20

"Aus wettbewerblicher Sicht ist es ein Hindernis und ein Nachteil für $GERN und seine Entwicklung von imetelstat."

https://twitter.com/adamfeuerstein/status/...cxt=HHwWgMC4wZ3mpoYsAAAA

 

10835 Postings, 2180 Tage VassagoGERN 2.40$

 
  
    #386
04.01.23 11:38
Heute werden die Phase3 Daten der IMerge Studie diskutiert. Bei negativen Daten halte ich einen Kursrückgang von über 70% für möglich. Sollte die Daten positiv ausfallen, bin ich gespannt, ob und wie weit der Kurs dann anspringen würde. Um 14 Uhr startet der CC.
https://ir.geron.com/investors/press-releases/...Phase-3/default.aspx  

10835 Postings, 2180 Tage VassagoGERN 3.76$ (vorbörslich +57%)

 
  
    #387
04.01.23 13:20

5267 Postings, 8333 Tage BiomediMein erster Thread war hier 2004

 
  
    #388
04.01.23 20:22
 

Optionen

2298 Postings, 1539 Tage BananiProposed Public Offering of Common Stock

 
  
    #389
05.01.23 07:32
Geron Corporation Announces Proposed Public Offering of Common Stock

...today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

https://finance.yahoo.com/news/...nces-proposed-public-211900778.html  

Optionen

10835 Postings, 2180 Tage VassagoGERN 2.87$ (vorbörslich -10%)

 
  
    #390
05.01.23 09:36
Das 175 Mio. $ Offering würgt den Kursanstieg natürlich ziemlich ab. Mal sehen zu welchem Preis je Aktie das Offering stattfinden soll.
https://ir.geron.com/investors/press-releases/...n-Stock/default.aspx
 

10835 Postings, 2180 Tage VassagoGERN 2.55$ (-20%)

 
  
    #391
05.01.23 19:29
Die Anküdigung des Offerings bringt den Kurs unter Druck.  

10835 Postings, 2180 Tage VassagoGERN 2.52$

 
  
    #392
06.01.23 18:35

Pricing

  • 55,8 Mio. neue Aktien zu je 2,45$
  • 25 Mio. warrants zu je 2,449$
  • Volumen insgesamt 198 Mio. $

https://ir.geron.com/investors/press-releases/...arrants/default.aspx


 

5267 Postings, 8333 Tage BiomediAktie ist ja im Aufwärtstrend...warum eigentlich?

 
  
    #393
25.01.23 13:01
Überlege nachzukaufen...da scheint irgendwas zu kommen  

Optionen

5267 Postings, 8333 Tage BiomediIst hier noch Jemand außer mir?

 
  
    #394
12.05.23 09:50
 

Optionen

Seite: < 1 | ... | 10 | 11 | 12 | 13 | 14 | 15 |
>  
   Antwort einfügen - nach oben